



July 22, 2019

Important Safety Information

The following products are shipped without charcoal bags, please open in a well-ventilated hood

DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic

DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic

Dear Valued Customer,

We are informing you that effective immediately, you will receive orders of the following products without the charcoal bags:

DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic (DIN 02329743);

DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic (DIN 02329751)

Due to the current shortage of these products, Jubilant DraxImage Inc., coordinated with Health Canada to release this product without the charcoal bags.

The product's quality, safety, efficacy and patient benefit/risk ratio are unaffected by the absence of the charcoal bag. The charcoal bag adsorbs radioactive iodine gas that may potentially be present during shipping. In addition, these charcoal bags are not required by the Canadian Nuclear Safety Commission.

As always, it is mandatory to adhere to the radiation safety controls as mandated per CNSC licensing requirements when handling **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic (DIN 02329743)** and **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic (DIN 02329751)**.

A Jubilant Pharma Company

OUR VALUES



Jubilant DraxImage Inc.
16751 Trans-Canada Highway
Kirkland, Québec, Canada H9H 4J4
Tel: +1-888-633-5343
Fax: +1-866-431-4288
www.draximage.com

Specifically, we remind you to avoid exposure to radioactive iodine gas by opening shipments of DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic (DIN 02329743) and DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic (DIN 02329751) in a well ventilated hood.

We are sorry for the inconvenience caused by this temporary shortage of **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic (DIN 02329743)** and **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic (DIN 02329751).**

Reporting Side Effects

Health care providers and patients are encouraged to report adverse events in patients taking **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Therapeutic (DIN 02329743)** and **DRAXIMAGE® Sodium Iodide I 131 Capsules, USP Diagnostic (DIN 02329751)** to Jubilant DraxImage Inc. at 1-888-633-5343.

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on [Adverse Reaction Reporting \(http://www.hc-sc.gc.ca/dhpmpps/medeff/report-declaration/index-eng.php\)](http://www.hc-sc.gc.ca/dhpmpps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax; or
- Call toll-free at 1-866-234-2345.

On behalf of Jubilant DraxImage Inc., we thank you for your continued support.

Kind regards,

A handwritten signature in blue ink, appearing to read 'Suzanne Bissonnette', with a long horizontal flourish extending to the right.

Suzanne Bissonnette
Global Therapeutics